Delivery Order SPE2DB24D2003-SPE2DB25FXJA8
- Not listed
- The Defense Logistics Agency awarded a $9,432.60 delivery order to AmerisourceBergen Drug Corp on April 28, 2025, for the supply of Multaq 400 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of April 29, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a $40,243.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on September 11, 2025, with an ultimate completion date of September 12, 2025. This non-competitive, competitively awarded delivery order represents a small-value pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,487.82 to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-set-aside award issued under competitive procedures. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a $2,624.44 firm fixed price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on August 12, 2025, with an ultimate completion date of August 13, 2025. This competitive award, which carries no set-aside designation, represents a pharmaceutical supply delivery to support federal medical procurement needs. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $2,110.62 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on June 25, 2025, with completion expected by June 26, 2025. This competitively awarded contract, issued without set-aside designation, represents a firm fixed price delivery order for pharmaceutical supply to support federal medical procurement needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Multaq 400 mg tablets (60-count units) valued at $1,725.96. This firm fixed price delivery order, issued on August 14, 2025, with completion targeted for August 15, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The award was made through open competition with no set-aside designation, and performance will be fulfilled from the...
- The Defense Logistics Agency Medical Supply Chain awarded a $57,770.08 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Multaq 400 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, with performance based in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and veteran...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $52,044.76 to supply Multaq 400 mg tablets (60-count units) under a firm fixed price contract. The order was competitively awarded with no set-aside designation and carries an ultimate completion date of September 19, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $3,200.00 for 60 tablets of Multaq 400 mg, a pharmaceutical product used in cardiac arrhythmia management. This was a competitively awarded, firm fixed-price delivery order with no set-aside designation, with performance completed by August 1, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg with a ceiling value of $20,863.60. This competitive, firm fixed-price delivery order was issued on April 25, 2025, with an ultimate completion date of April 28, 2025. The award is performance-based in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXJA8Delivery Order
The Defense Logistics Agency (DLA) awarded a $3,059.76 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on May 27, 2025, with completion scheduled for May 28, 2025. This firm fixed-price contract, issued without set-aside restrictions, represents a competitive procurement for pharmaceutical supplies supporting federal medical needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems through the DLA Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates consistent capability to meet procurement requirements across multiple therapeutic domains, including specialty medications, vaccines, and medical supplies for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 5/27/25 |